Neoadjuvant nivolumab shows long-term benefit in patients with non–small cell lung cancer
Patients with resectable non–small cell lung cancer (NSCLC) who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes, according to results ...
Feb 15, 2023
0
6